Post Spinal Anaesthesia HypotensionNCT07706426
This is a Study That Aims to Estimate the Effect of Maternal Body Mass Index on the Prophylactic Dose of Norepinephrine Infusion for Preventing Hypotension in Parturient After Spinal Anesthesia
A study testing Nor-epinephrine and Normal Saline in people with Post Spinal Anaesthesia Hypotension, run by Ain Shams University at 1 site in Egypt.
Trial summary
This is a randomized, double-blinded controlled study that aims to estimate the effect of maternal body mass index on the prophylactic dose of norepinephrine infusion for preventing hypotension in parturient after spinal anesthesia. Read more about this study
- Who is it for?
- Ages 18 to 40 years, women only
- Conditions the study is for
- Post Spinal Anaesthesia Hypotension
- What is being tested?
- Nor-epinephrine and Normal Saline
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteEgypt
- Study dates
- 9 Jul 2026to 20 Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- A normal singleton pregnancy with a gestational age of ≥ 37 weeks. 18-40 years old pregnant women scheduled for elective C/S under spinal anesthesia.
Who cannot join
- Any absolute contraindication to spinal block, Neurological or cardiac disorder, Basal systolic blood pressure above 140 mmHg or below 100 mmHg, Peripartum bleeding or emergent situations both for fetus and mother, Those who refused to participate in the study were excluded Known fetal abnormality, intrauterine growth restriction, Obstetric complication (ruptured membranes, placenta previa, placental abruption),
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effect of Maternal Body Mass Index on the Prophylactic Dose of Norepinephrine Infusion for Preventing Hypotension in Parturient After Spinal Anesthesia
This is a randomized, double-blinded controlled study that aims to estimate the effect of maternal body mass index on the prophylactic dose of norepinephrine infusion for preventing hypotension in parturient after spinal anesthesia.
Read the detailed description
This is a randomized, double-blinded controlled study that aims to estimate the effect of maternal body mass index on the prophylactic dose of norepinephrine infusion for preventing hypotension in parturient after spinal anesthesia.
Routine preoperative investigations will be done to all patients including laboratory investigations as (complete blood picture, prothrombin time and partial thromboplastin time), age and BMI will be recorded.
All the patients will be fasting for solid food for 6-8 hours and for clear fluids for 4 hours before surgery.
Upon entry into the operating theater, all patients will be placed under standard American Society of Anesthesiologist (ASA) monitoring including 5-lead electrocardiography, pulse oximetry and non-invasive blood pressure. Baseline values of systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR) and mean blood pressure (MBP) will be measured in supine position with left uterine displacement (15 degree wedge under the right buttock) and recorded as the arithmetic mean of three consecutive measurements at least 2 min intervals with a difference of less than 10%.
As per standard practice, SBP, DBP, MBP, HR and pulse oximetry measurements will be recorded in every 2 min throughout the surgery. An 18-gauge cannula will be inserted into a large vein, The patients will receive no premedication. The study period will be the interval between the initiation of spinal injection and delivery of the fetus .
Subarachnoid block will be performed through L3-4 or L4-5 intervertebral space in the sitting position. A solution of 12.5 mg 0.5% hyperbaric bupivacaine plus 25 mic fentanyl will be injected into subarachnoid space using a 25-gauge pencil point spinal needle. After completion of subarachnoid injection, patients will be immediately placed supine on the operating table with left uterine displacement using a 15° wedge .
The highest level of sensory blockade will be assessed using a sterile needle, surgery will be permitted after a bilateral T6 sensory block .
To assure blinding, the study group will be known only to the research assistant, who would be responsible for each step of the NE administration including starting dose of NE infusion, applying a bolus dose or cessation of the infusion of NE according to the study protocol .
Immediately after the injection of the spinal anesthetic, patients will have a norepinephrine protocol corresponding to the randomized group. The study drug will be started intravenously at a rate of 50 ml/h, Lactated Ringer's solution warmed at 37°C will also administered, starting with a loading dose of 10 ml/kg given rapidly over 15 minutes and will then be adjusted to a slow maintenance flow rate to keep the vein open .
After delivery, an intravenous infusion of oxytocin (20 IU) will be slowly administered. After the end of surgery, the mother will be transported to the recovery room with routine monitoring .
NE infusion will be stopped 5 min after delivery in all patients . The intraoperative period will be divided into 2 consecutive periods . The first period is called the post-spinal period and will include the period between the completion of subarachnoid block and the time of delivery.
The subsequent period between the time of delivery and the end of the surgery will be called the post-delivery period.
All complications will be entitled according to the period in which they occurred. Accordingly, post spinal hypotension (PSH) and post delivery hypotension (PDH) will be defined as a reduction in SBP of 20% or more of the baseline value before and after the delivery, respectively .
Similarly, post-spinal severe hypotension (PSSH) and post-delivery severe hypotension (PDSH) will be defined as a decrease in SBP of 40% or more from the baseline value before and after the delivery respectively.
Management of complications: .
- If PSH or PDH was developed, a bolus of 10 mg ephedrine will be administered.
- If hypotension persisted after 2 min, a repeated dose of 10 mg ephedrine i.v. will be administered again.
- If PSSH or PDSH occurred, 15 mg ephedrine i.v. bolus will administered.
- In case of bradycardia (heart rate less than 60 beats per min ) without maternal hypotension, NE infusion will be stopped.
- If bradycardia persists for 2 min despite discontinuation of NE infusion, 0.5 mg of atropine i.v. bolus will be administered.
- Moreover, if the heart rate falls below 50 beats per min , 0.5 mg atropine i.v. bolus will be administered without waiting for 2 min. As soon as the HR increases above 60 beats per min, NE infusion will be started again at the same infusion dose corresponding to the NE group that the patient is randomized.
- If bradycardia is accompanied by hypotension, 10 mg ephedrine i.v. bolus will be administered.
- In contrast to hypotension, if the SBP is found to be 20% above the basal value, the NE infusion will be stopped and recorded as a hypertensive episode. If the systolic blood pressure falls below this determined hypertensive value, NE will be restarted at the same dose.
- Incidence of maternal complication as nausea and vomiting will be recorded and treated with granitryl (1 mg IV) Apgar score after delivery. Apgar score at 1 and 5 min will be recorded after delivery by the attending pediatric physician.
Hemodynamic changes mentioned above and the number of interventions including administration of ephedrine or atropine, stopping or re-starting of NE infusion, which will be applied by the physician to overcome the hemodynamic consequences of spinal anesthesia will all be recorded until the patient leaves the operating room.
- Conditions
- Post Spinal Anaesthesia Hypotension
- Being tested
- Nor-epinephrine, Normal Saline
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nor-epinephrineDrug
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Normal SalineDrug
normal saline infusion post spinal anesthesia .
| Study group | Role | What they receive |
|---|---|---|
| Non_obese + NE 0 mic/kg/min | Placebo comparator | Non_obese Patients BMI <30 kg/m2 receiving placebo (normal saline )infusion after spinal anesthesia. Receives: Drug: Normal Saline |
| Non_obese + NE 0.025mic/kg/min | Active comparator | Non_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.025mic/kg/min after spinal anesthesia. Receives: Drug: Nor-epinephrine |
| Non_obese + NE 0.05mic/kg/min | Active comparator | Non_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.05mic/kg/min after spinal anesthesia. Receives: Drug: Nor-epinephrine |
| Non_obese + NE 0.075mic/kg/min | Active comparator | Non_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.075mic/kg/min after spinal anesthesia. Receives: Drug: Nor-epinephrine |
| Non_obese + NE 0.1mic/kg/min | Active comparator | Non_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.1mic/kg/min after spinal anesthesia. Receives: Drug: Nor-epinephrine |
| Obese + NE 0 mic/kg/min | Placebo comparator | Obese Patients BMI >30 kg/m2 receiving placebo (normal saline )infusion after spinal anesthesia. Receives: Drug: Normal Saline |
| Obese + NE 0.025 mic/kg/min | Active comparator | Obese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.025 mic/kg/min after spinal anesthesia. Receives: Drug: Nor-epinephrine |
| Obese + NE 0.05 mic/kg/min | Active comparator | Obese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.05 mic/kg/min after spinal anesthesia. Receives: Drug: Nor-epinephrine |
| Obese + NE 0.075 mic/kg/min | Active comparator | Obese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.075 mic/kg/min after spinal anesthesia. Receives: Drug: Nor-epinephrine |
| Obese + NE 0.1 mic/kg/min | Active comparator | Obese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.1 mic/kg/min after spinal anesthesia. Receives: Drug: Nor-epinephrine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of hypotension after spinal anesthesia
Hypotension defined as a ≥20% decrease in systolic blood pressure from baseline.
Measured: From spinal anesthesia until delivery of the fetus.
Secondary outcomes (6)
Reactive hypertension
Incidence of systolic blood pressure ≥20% above baseline.
Measured: From spinal anesthesia until the end of surgery.
Bradycardia
Heart rate <60 beats/min.
Measured: From spinal anesthesia until the end of surgery.
Nausea and vomiting
Incidence of maternal nausea and/or vomiting.
Measured: From spinal anesthesia until the end of surgery.
Apgar score at 1 minute
Neonatal Apgar score.
Measured: 1 minute after delivery.
Apgar score at 5 minutes
Neonatal Apgar score.
Measured: 5 minutes after delivery.
Number of rescue interventions
Number of ephedrine doses, atropine doses, and norepinephrine infusion interruptions/restarts.
Measured: From spinal anesthesia until the patient leaves the operating room.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2026
- Study start9 Jul 2026 (estimated)
- Primary completion20 Jan 2027 (estimated)
- Study completion20 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Post Spinal Anaesthesia HypotensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07706426
- Sponsor's protocol ID
- FMASU MD 46/2026
- Status last verified
- Jul 2026
- First submitted
- 11 Jul 2026
- Last updated
- 15 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Maternal Body Mass Index on the Prophylactic Dose of Norepinephrine Infusion for Preventing Hypotension in Parturient After Spinal Anesthesia
- ClinicalTrials.gov ID
- NCT07706426
- Acronym / sponsor ID
- FMASU MD 46/2026
- Conditions
- Post Spinal Anaesthesia Hypotension
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 9 Jul 2026 (estimated)
- Primary completion
- 20 Jan 2027 (estimated)
- Study completion
- 20 Apr 2027 (estimated)
- First posted
- 15 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, double-blinded controlled study that aims to estimate the effect of maternal body mass index on the prophylactic dose of norepinephrine infusion for preventing hypotension in parturient after spinal anesthesia.
Detailed description
This is a randomized, double-blinded controlled study that aims to estimate the effect of maternal body mass index on the prophylactic dose of norepinephrine infusion for preventing hypotension in parturient after spinal anesthesia.
Routine preoperative investigations will be done to all patients including laboratory investigations as (complete blood picture, prothrombin time and partial thromboplastin time), age and BMI will be recorded.
All the patients will be fasting for solid food for 6-8 hours and for clear fluids for 4 hours before surgery.
Upon entry into the operating theater, all patients will be placed under standard American Society of Anesthesiologist (ASA) monitoring including 5-lead electrocardiography, pulse oximetry and non-invasive blood pressure. Baseline values of systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR) and mean blood pressure (MBP) will be measured in supine position with left uterine displacement (15 degree wedge under the right buttock) and recorded as the arithmetic mean of three consecutive measurements at least 2 min intervals with a difference of less than 10%.
As per standard practice, SBP, DBP, MBP, HR and pulse oximetry measurements will be recorded in every 2 min throughout the surgery. An 18-gauge cannula will be inserted into a large vein, The patients will receive no premedication. The study period will be the interval between the initiation of spinal injection and delivery of the fetus .
Subarachnoid block will be performed through L3-4 or L4-5 intervertebral space in the sitting position. A solution of 12.5 mg 0.5% hyperbaric bupivacaine plus 25 mic fentanyl will be injected into subarachnoid space using a 25-gauge pencil point spinal needle. After completion of subarachnoid injection, patients will be immediately placed supine on the operating table with left uterine displacement using a 15° wedge .
The highest level of sensory blockade will be assessed using a sterile needle, surgery will be permitted after a bilateral T6 sensory block .
To assure blinding, the study group will be known only to the research assistant, who would be responsible for each step of the NE administration including starting dose of NE infusion, applying a bolus dose or cessation of the infusion of NE according to the study protocol .
Immediately after the injection of the spinal anesthetic, patients will have a norepinephrine protocol corresponding to the randomized group. The study drug will be started intravenously at a rate of 50 ml/h, Lactated Ringer's solution warmed at 37°C will also administered, starting with a loading dose of 10 ml/kg given rapidly over 15 minutes and will then be adjusted to a slow maintenance flow rate to keep the vein open .
After delivery, an intravenous infusion of oxytocin (20 IU) will be slowly administered. After the end of surgery, the mother will be transported to the recovery room with routine monitoring .
NE infusion will be stopped 5 min after delivery in all patients . The intraoperative period will be divided into 2 consecutive periods . The first period is called the post-spinal period and will include the period between the completion of subarachnoid block and the time of delivery.
The subsequent period between the time of delivery and the end of the surgery will be called the post-delivery period.
All complications will be entitled according to the period in which they occurred. Accordingly, post spinal hypotension (PSH) and post delivery hypotension (PDH) will be defined as a reduction in SBP of 20% or more of the baseline value before and after the delivery, respectively .
Similarly, post-spinal severe hypotension (PSSH) and post-delivery severe hypotension (PDSH) will be defined as a decrease in SBP of 40% or more from the baseline value before and after the delivery respectively.
Management of complications: .
- If PSH or PDH was developed, a bolus of 10 mg ephedrine will be administered.
- If hypotension persisted after 2 min, a repeated dose of 10 mg ephedrine i.v. will be administered again.
- If PSSH or PDSH occurred, 15 mg ephedrine i.v. bolus will administered.
- In case of bradycardia (heart rate less than 60 beats per min ) without maternal hypotension, NE infusion will be stopped.
- If bradycardia persists for 2 min despite discontinuation of NE infusion, 0.5 mg of atropine i.v. bolus will be administered.
- Moreover, if the heart rate falls below 50 beats per min , 0.5 mg atropine i.v. bolus will be administered without waiting for 2 min. As soon as the HR increases above 60 beats per min, NE infusion will be started again at the same infusion dose corresponding to the NE group that the patient is randomized.
- If bradycardia is accompanied by hypotension, 10 mg ephedrine i.v. bolus will be administered.
- In contrast to hypotension, if the SBP is found to be 20% above the basal value, the NE infusion will be stopped and recorded as a hypertensive episode. If the systolic blood pressure falls below this determined hypertensive value, NE will be restarted at the same dose.
- Incidence of maternal complication as nausea and vomiting will be recorded and treated with granitryl (1 mg IV) Apgar score after delivery. Apgar score at 1 and 5 min will be recorded after delivery by the attending pediatric physician.
Hemodynamic changes mentioned above and the number of interventions including administration of ephedrine or atropine, stopping or re-starting of NE infusion, which will be applied by the physician to overcome the hemodynamic consequences of spinal anesthesia will all be recorded until the patient leaves the operating room.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 10
| Arm | Type | Receives |
|---|---|---|
| Non_obese + NE 0 mic/kg/min | Placebo comparator | Drug: Normal SalineNon_obese Patients BMI <30 kg/m2 receiving placebo (normal saline )infusion after spinal anesthesia. |
| Non_obese + NE 0.025mic/kg/min | Active comparator | Drug: Nor-epinephrineNon_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.025mic/kg/min after spinal anesthesia. |
| Non_obese + NE 0.05mic/kg/min | Active comparator | Drug: Nor-epinephrineNon_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.05mic/kg/min after spinal anesthesia. |
| Non_obese + NE 0.075mic/kg/min | Active comparator | Drug: Nor-epinephrineNon_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.075mic/kg/min after spinal anesthesia. |
| Non_obese + NE 0.1mic/kg/min | Active comparator | Drug: Nor-epinephrineNon_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.1mic/kg/min after spinal anesthesia. |
| Obese + NE 0 mic/kg/min | Placebo comparator | Drug: Normal SalineObese Patients BMI >30 kg/m2 receiving placebo (normal saline )infusion after spinal anesthesia. |
| Obese + NE 0.025 mic/kg/min | Active comparator | Drug: Nor-epinephrineObese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.025 mic/kg/min after spinal anesthesia. |
| Obese + NE 0.05 mic/kg/min | Active comparator | Drug: Nor-epinephrineObese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.05 mic/kg/min after spinal anesthesia. |
| Obese + NE 0.075 mic/kg/min | Active comparator | Drug: Nor-epinephrineObese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.075 mic/kg/min after spinal anesthesia. |
| Obese + NE 0.1 mic/kg/min | Active comparator | Drug: Nor-epinephrineObese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.1 mic/kg/min after spinal anesthesia. |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- A normal singleton pregnancy with a gestational age of ≥ 37 weeks. 18-40 years old pregnant women scheduled for elective C/S under spinal anesthesia.
Key exclusion criteria (1 listed)
- Any absolute contraindication to spinal block, Neurological or cardiac disorder, Basal systolic blood pressure above 140 mmHg or below 100 mmHg, Peripartum bleeding or emergent situations both for fetus and mother, Those who refused to participate in the study were excluded Known fetal abnormality, intrauterine growth restriction, Obstetric complication (ruptured membranes, placenta previa, placental abruption),
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nor-epinephrinenorepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia . | Drug | Non_obese + NE 0.025mic/kg/min, Non_obese + NE 0.05mic/kg/min, Non_obese + NE 0.075mic/kg/min, Non_obese + NE 0.1mic/kg/min, Obese + NE 0.025 mic/kg/min, Obese + NE 0.05 mic/kg/min, Obese + NE 0.075 mic/kg/min, Obese + NE 0.1 mic/kg/min |
| Normal Salinenormal saline infusion post spinal anesthesia . | Drug | Non_obese + NE 0 mic/kg/min, Obese + NE 0 mic/kg/min |
Primary outcome
Incidence of hypotension after spinal anesthesia
Time frame: From spinal anesthesia until delivery of the fetus.
Hypotension defined as a ≥20% decrease in systolic blood pressure from baseline.
6 secondary outcomes
Reactive hypertension
Time frame: From spinal anesthesia until the end of surgery.
Bradycardia
Time frame: From spinal anesthesia until the end of surgery.
Nausea and vomiting
Time frame: From spinal anesthesia until the end of surgery.
Apgar score at 1 minute
Time frame: 1 minute after delivery.
Apgar score at 5 minutes
Time frame: 5 minutes after delivery.
Number of rescue interventions
Time frame: From spinal anesthesia until the patient leaves the operating room.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2026.
Related trials for Post Spinal Anaesthesia Hypotension
Enrolling by invitation
Comparison Between Intravenous Hydrocortisone and Ondansetron in Prevention of Post Spinal Anesthesia Hypotension
Post Spinal Anaesthesia Hypotension
RecruitingPhase 4
Effect of Dexamethasone on Post-spinal Hypotension
Post Spinal Anaesthesia Hypotension, Geriatric Population
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nor-epinephrine and Normal Saline in people with Post Spinal Anaesthesia Hypotension, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Merna M.k. Mohy, M.SC (+201065606283, mernakamal77@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of hypotension after spinal anesthesia (time frame: From spinal anesthesia until delivery of the fetus.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2026; AzTrials last refreshed its copy on 27 Oct 2026.